

## Medical/Pharmaceutical Supply Chain Security

Pending Legislation

- S. 3538, Strengthening America's Supply Chain and National Security Act (Senator Rubio)

Would require companies to report on the sources of their APIs and would tighten laws encouraging the U.S. Department of Veteran Affairs to buy American pharmaceuticals. The bill calls for federal financing guarantees to **U.S. medical supply companies** with production in the United States and would increase the tax deduction temporarily for businesses investing in **medical equipment and facilities** related to COVID-19.

- S. 3343, The Medical Supply Chain Security Act (Senator Josh Hawley)

Calls for enhanced security of the medical supply chain and enhanced FDA authority to request information about the sources of drugs **and medical devices**. It would require medical device manufacturers to report expected shortages to the FDA. A companion bill, H.R. 6049, was introduced in the House of Representatives on March 2, 2020.

- S. 3537, Protecting Our Pharmaceutical Supply Chain from China Act of 2020 (Senator Tom Cotton)

Would require the FDA to establish a registry to track APIs and institute a country-of-origin label for imported drugs. The bill would provide economic incentives for producing pharmaceuticals **and medical equipment** in the United States. The bill also would prohibit federal agencies and health facilities from purchasing APIs and other pharmaceutical products manufactured in China without an FDA waiver certifying that China is the sole source.

- H.R. 5982, The Safe Medicine Act (Rep. Bill Posey)

Would direct HHS to assess vulnerabilities in the U.S. pharmaceutical supply chain by issuing a report that examines U.S. dependence on China for critical APIs and gaps in domestic pharmaceutical manufacturing capabilities.

- H.R. 4710, The Pharmaceutical Independence Long-Term Readiness Act (Rep. John Garamendi)

Would direct the Department of Defense to include a section in each national defense strategy that outlines steps to address gaps in the U.S. pharmaceutical manufacturing base and strengthen pharmaceutical supply chains with single points of failure.